Updates are available Erratum dated 2015-06-11
Click to view Erratum: https://doi.org/10.1038/cddis.2015.164
-
Authors
Cencioni, M T
Santini, S
Ruocco, G
Borsellino, G
De Bardi, M
Grasso, M G
Ruggieri, S
Gasperini, C
Centonze, D
Barilá, D
Battistini, L
Volpe, E
- License Information
-
More Information
Article History
Received: 23 September 2014
Revised: 13 February 2015
Accepted: 27 February 2015
First Online: 7 May 2015
Change Date: 11 June 2015
Change Type: Correction
Change Details: This article has been corrected since Online Publication and a corrigendum has also been published
Competing interests
: DC acted as an Advisory Board member of Merck-Serono, Teva, Bayer Schering, Biogen Idec, Novartis, Almirall and GW Pharmaceuticals and received funding for travelling and honoraria for speaking or consultation fees from Merck-Serono, Teva, Novartis, Bayer Schering, Sanofi-aventis, Biogen Idec and Almirall. He is the principal investigator in clinical trials for Novartis, Merck-Serono, Teva, Bayer Schering, Sanofi-aventis, Biogen Idec and Roche. The remaining authors declare no conflicts of interest.
